Libertini Michela, Hallin Magnus, Thway Khin, Noujaim Jonathan, Benson Charlotte, van der Graaf Winette, Jones Robin L
Royal Marsden Hospital/Institute of Cancer Research, London, UK.
Maisonneuve-Rosemont Hospital, Montreal, Canada.
Int J Surg Pathol. 2021 Feb;29(1):4-20. doi: 10.1177/1066896920958120. Epub 2020 Sep 10.
Gynecological sarcomas represent 3% to 4% of all gynecological malignancies and 13% of all sarcomas. The uterus is the most frequent primary site (83%); less frequently sarcomas are diagnosed originating from the ovary (8%), vulva and vagina (5%), and other gynecologic organs (2%). As the classification of gynecologic sarcomas continues to diversify, so does the management. Accurate histopathologic diagnosis, utilizing appropriate ancillary immunohistochemical and molecular analysis, could lead to a more personalized approach. However, there are subtypes that require further definition, with regard to putative predictive markers and optimal management. The aim of this review is to highlight the importance of accurate diagnosis and classification of gynecologic sarcoma subtypes by the surgical pathologist in order to provide more tailored systemic treatment, and to highlight the increasing importance of close collaboration between the pathologist and the oncologist.
妇科肉瘤占所有妇科恶性肿瘤的3%至4%，占所有肉瘤的13%。子宫是最常见的原发部位（83%）；较少见的是起源于卵巢（8%）、外阴和阴道（5%）以及其他妇科器官（2%）的肉瘤。随着妇科肉瘤的分类不断多样化，其治疗方法也在不断变化。利用适当的辅助免疫组织化学和分子分析进行准确的组织病理学诊断，可能会带来更个性化的治疗方法。然而，对于一些亚型，在假定的预测标志物和最佳治疗方面仍需要进一步明确。本综述的目的是强调手术病理学家准确诊断和分类妇科肉瘤亚型的重要性，以便提供更具针对性的全身治疗，并强调病理学家与肿瘤学家密切合作的重要性日益增加。
